Bacil Pharma Board Approves Rights Issue of Up To ₹50 Crore and Share Capital Increase
Bacil Pharma Ltd, during a meeting of its Board of Directors held on July 9, 2026, approved several significant corporate initiatives. The Board sanctioned a proposal for raising funds through a Rights Issue of equity shares and authorized an increase in the company's Authorized Share Capital.The board unanimously approved the plan to raise up to ₹50,00,00,000 (Rupees Fifty Crores Only) by way of a Rights Issue of equity shares. This issuance will be open to all eligible equity shareholders. The details regarding the Right Issue, including terms, issue price, rights entitlement ratio, and record date, are subject to determination by the Board of Directors or its appointed committee in due course.
The company's authorized capital structure was also approved for expansion. The Board sanctioned an increase in Authorized Share Capital by Rs. 45,00,00,000 (Rupees Forty-Five Crores Only). This increase will be structured into 4,50,00,000 equity shares of ₹10/- each face value. Following this change, the post-increase authorized capital of the company will stand at Rs. 65,00,00,000 (Rupees Sixty-Five Crores Only). This alteration requires subsequent approval from the shareholders at a forthcoming General Meeting.
Governance and Committee Appointments
The Board meeting addressed several key personnel and structural matters:Director Resignations: The board formally accepted the resignations of Mr. Dinesh Chander Notiyal, an Independent Director, and Ms. Avani Savjibhai Godhaniya, also an Independent Director.
Right Issue Committee: A dedicated Right Issue Committee was approved by the Board to manage the process. Members appointed to the committee include:
| Name | Designation on Board | Role in Right Issue Committee |
|---|---|---|
| Chaitali Kalpataru Shah | Executive Director & CFO | Chairman |
| Vivek Mukesh Yadav | Independent Director | Member |
| Omprakash Pyarelal Sonar | Independent Director | Member |
Intermediaries and Delegation of Authority
The Board took record of the appointment of essential intermediaries for the Rights Issue process. These appointments include:| Role | Entity Name | Details |
|---|---|---|
| Registrar for Right Issue | M/s Purva Sharegistry (India) Private Limited | 9 Shiv Shakti Industrial Estate, J R Boricha Marg, Lower Parel (E), Mumbai |
| Banker to the Issue | Axis Bank Limited | Sakinaka Branch, Andheri Mumbai |
| Monitoring Agency | Acuité Ratings & Research Limited | Designated as Monitoring Agency |
Furthermore, Ms. Chaitali Kalpataru Shah (Executive Director & CFO) and the Company Secretary were authorized by the Board of Directors to execute all necessary applications, documents, undertakings, deeds, and agreements pertaining to the approved Right Issue proposal on behalf of the company.
The Trading Window for dealing in the securities of the company remains closed for all designated persons and their immediate relatives until 48 hours after the declaration of the outcome of the Board Meeting.
Stock Price Movement
Bacil Pharma Ltd settled at ₹38.36 in post-market trading on Thursday, after ticking up 1.16%. Throughout the day, shares moved within a range that spanned from a low of ₹37.19 to an intraday high of ₹38.70.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: